JP2022547331A5 - - Google Patents
Info
- Publication number
- JP2022547331A5 JP2022547331A5 JP2022516159A JP2022516159A JP2022547331A5 JP 2022547331 A5 JP2022547331 A5 JP 2022547331A5 JP 2022516159 A JP2022516159 A JP 2022516159A JP 2022516159 A JP2022516159 A JP 2022516159A JP 2022547331 A5 JP2022547331 A5 JP 2022547331A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- chemical formula
- pharmaceutically acceptable
- acceptable salt
- melanoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025021639A JP2025087716A (ja) | 2019-09-12 | 2025-02-13 | 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート |
| JP2025110172A JP2025138792A (ja) | 2019-09-12 | 2025-06-30 | 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート |
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962899615P | 2019-09-12 | 2019-09-12 | |
| US201962899611P | 2019-09-12 | 2019-09-12 | |
| US201962899618P | 2019-09-12 | 2019-09-12 | |
| US62/899,611 | 2019-09-12 | ||
| US62/899,618 | 2019-09-12 | ||
| US62/899,615 | 2019-09-12 | ||
| US201962946870P | 2019-12-11 | 2019-12-11 | |
| US62/946,870 | 2019-12-11 | ||
| US202062956844P | 2020-01-03 | 2020-01-03 | |
| US202062956907P | 2020-01-03 | 2020-01-03 | |
| US62/956,844 | 2020-01-03 | ||
| US62/956,907 | 2020-01-03 | ||
| PCT/US2020/050459 WO2021050917A1 (en) | 2019-09-12 | 2020-09-11 | Phospholipid ether conjugates as cancer-targeting drug vehicles |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025021639A Division JP2025087716A (ja) | 2019-09-12 | 2025-02-13 | 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート |
| JP2025110172A Division JP2025138792A (ja) | 2019-09-12 | 2025-06-30 | 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022547331A JP2022547331A (ja) | 2022-11-11 |
| JP2022547331A5 true JP2022547331A5 (cg-RX-API-DMAC10.html) | 2023-09-22 |
| JP7749542B2 JP7749542B2 (ja) | 2025-10-06 |
Family
ID=74866023
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022516159A Active JP7749542B2 (ja) | 2019-09-12 | 2020-09-11 | 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート |
| JP2025021639A Pending JP2025087716A (ja) | 2019-09-12 | 2025-02-13 | 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート |
| JP2025110172A Pending JP2025138792A (ja) | 2019-09-12 | 2025-06-30 | 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025021639A Pending JP2025087716A (ja) | 2019-09-12 | 2025-02-13 | 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート |
| JP2025110172A Pending JP2025138792A (ja) | 2019-09-12 | 2025-06-30 | 癌標的薬物ビヒクルとしてのリン脂質エーテルコンジュゲート |
Country Status (11)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019200017A1 (en) * | 2018-04-10 | 2019-10-17 | Cellectar Biosciences, Inc. | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy |
| MX2022003044A (es) * | 2019-09-12 | 2022-06-02 | Cellectar Biosciences Inc | Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer. |
| KR102973364B1 (ko) * | 2019-10-10 | 2026-06-04 | 셀렉타 바이오사이언시스, 인코퍼레이티드 | 인지질-플라바글린 접합체 및 표적화된 암 치료를 위해 이를 사용하는 방법 |
| CN113816990B (zh) * | 2021-03-22 | 2023-08-22 | 联宁（苏州）生物制药有限公司 | 修饰的氨基酸及其在adc中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8540968B2 (en) * | 2004-03-02 | 2013-09-24 | Cellectar, Inc. | Phospholipid ether analogs as agents for detecting and locating cancer, and methods thereof |
| WO2011031919A2 (en) * | 2009-09-11 | 2011-03-17 | Cellectar, Inc. | Non-radioactive phospholipid compounds, compositions, and methods of use |
| CN107708702A (zh) * | 2014-11-17 | 2018-02-16 | 塞勒克塔生物科学有限公司 | 磷脂醚类似物作为靶向癌症的药物载体 |
| CN109310702A (zh) * | 2016-05-20 | 2019-02-05 | 芝加哥大学 | 用于化学疗法、靶向疗法、光动力疗法、免疫疗法和它们的任何组合的纳米颗粒 |
| CN109791152B (zh) * | 2016-06-14 | 2023-03-03 | 塞勒科塔生物科学公司 | 用于鉴定和分离循环肿瘤细胞的磷脂醚类似物 |
| WO2019200017A1 (en) * | 2018-04-10 | 2019-10-17 | Cellectar Biosciences, Inc. | Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy |
| MX2022003044A (es) * | 2019-09-12 | 2022-06-02 | Cellectar Biosciences Inc | Conjugados de éter de fosfolípido como vehículos de fármacos que focalizan el cáncer. |
-
2020
- 2020-09-11 MX MX2022003044A patent/MX2022003044A/es unknown
- 2020-09-11 US US17/642,561 patent/US20230066517A1/en active Pending
- 2020-09-11 JP JP2022516159A patent/JP7749542B2/ja active Active
- 2020-09-11 WO PCT/US2020/050459 patent/WO2021050917A1/en not_active Ceased
- 2020-09-11 CA CA3150991A patent/CA3150991A1/en active Pending
- 2020-09-11 BR BR112022004482A patent/BR112022004482A2/pt unknown
- 2020-09-11 AU AU2020346898A patent/AU2020346898B2/en active Active
- 2020-09-11 KR KR1020227011911A patent/KR20220062363A/ko active Pending
- 2020-09-11 EP EP20862948.5A patent/EP4028018A4/en active Pending
- 2020-09-11 CN CN202080074564.3A patent/CN114599371A/zh active Pending
-
2022
- 2022-03-08 IL IL291197A patent/IL291197A/en unknown
-
2025
- 2025-02-13 JP JP2025021639A patent/JP2025087716A/ja active Pending
- 2025-06-30 JP JP2025110172A patent/JP2025138792A/ja active Pending
-
2026
- 2026-06-11 AU AU2026204469A patent/AU2026204469A1/en active Pending